Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study

Chin Med J (Engl). 2023 Jun 5;136(11):1358-1360. doi: 10.1097/CM9.0000000000002399.

Authors

Meng Chai¹, Haitao Zhang², Lixia Yang¹, Jing Liang¹, Hongya Han¹, Xiaoli Liu¹, Xiaoteng Ma¹, Yan Liu¹, Dongmei Shi¹, Yingxin Zhao¹, Yuyang Liu¹, Yujie Zhou¹

Affiliations

¹ Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing 100029, China.
² Department of Cardiology, Air Force Medical Center, Beijing 100142, China.

No abstract available

MeSH terms

Anticholesteremic Agents* / adverse effects
Cardiovascular Diseases* / chemically induced
Cardiovascular Diseases* / drug therapy
East Asian People
Heart Disease Risk Factors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Lipids
Risk Factors
Treatment Outcome

Substances

evolocumab
Lipids
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors